2014 Results. Information meeting 30 March 2015

Transcription

1 2014 Results Information meeting 30 March

2 Table of contents 1. Compliance, a public health challenge Dominique Pautrat 2. Financial results on 31 Dec 2014 Jean-Yves Samson activity and outlooks Dominique Pautrat 4. Conclusion Dominique Pautrat 30 March Annual Results 2

3 Compliance A public health challenge and a strategic direction for the Pharmagest Group 3

4 Compliance: a public health challenge E-Health 50% of all treatments in the world are followed poorly or to a low extent (WHO Study on Adherence) In France, the average rate of compliant patients is 40% (CRIP*/IMS Health France Study November 2014) Significant consequences for the state of patients' health and the health system economy In France, 8,000 to 12,000 deaths per year are due to noncompliance, representing up to 1,000,000 days of hospitalisation (Jalma Observatory June 2014) Estimated cost of 9.3 billion per year in France (CRIP*/IMS Health France Study November 2014) *CRIP=Pharmaceutical Industry Think Tank 4

5 Compliance: a public health challenge E-Health This data is confirmed by an Opinionway - Welcoop study carried out in November 2014* Less than 1/2 have completed their treatment Significant consequences for the state of patients' HAVE health and the health FOLLOWED system economy ONLY HAVE PARTLY FOLLOWED THE TREATMENT THE TREATMENT EXACTLY * (1,014 people questioned, of whom 567 were under treatment) 5

6 New Technologies for Serving E-Health Patients The Opinionway Welcoop study reveals the expectations of French people with regard to new technologies and connected devices in the healthcare field A PILL DISPENSER ELECTRONIC OR INTELLIGENT MORE INFORMATION ON THE COSEQUENCES OF POOR COMPLIANCE A SOLUTION: E-HEALTH REMINDER TEXTS MORE INFORMATION ON THE ILLNESS AND ITS PROGRESSION MORE EXPLANATION OF TREATMENTS DIGITAL TOOLS WEBSITES, APPS, etc. 6

7 The pharmacist: a central role E-Health The pharmacist is known for - Being a healthcare professional and the knowledge that brings, - Being available, - Having trusting relationships with customers. Pharmacists must play an important role in compliance at several levels: - Providing clear information on dosages, - Detecting non-compliant patients, - Putting in place pharmaceutical meetings, - Proposing solutions and products to help improve compliance. 7

8 Compliance: PHARMAGEST's E-Health answers The PHARMAGEST Group's strategy is clearly oriented towards helping pharmacists to monitor patient compliance: Providing clear information on dosages - Printing of dosage regimens and labels; - Displaying of originators for generic drugs. 8

9 Compliance: PHARMAGEST's E-Health answers Detecting non-compliant patients Targeting and screening of non-compliant patients during dispensing using a questionnaire: - Targeted based on patient profiles; - Automatically offered during dispensing. 9

10 Compliance: PHARMAGEST's E-Health answers New Technologies for Compliance The application Ma Pharmacie Mobile : - Sending of reminders when medication should be taken; - Patient confirmation that medication has been taken allows the pharmacist to establish a compliance report. Sending of text messages to patients by the pharmacist to remind them to renew their treatment or prescription. 10

11 Compliance: PHARMAGEST's E-Health answers New Technologies for Compliance The Compliance Monitoring Software - Integrated chronic care programmes; - Appointment management; - Monitoring of constants; - Support & help; - Secure data storage (HDS). 11

12 Compliance: PHARMAGEST's E-Health answers New Technologies for Compliance Ensuring that medication is taken using the DO-Pill SecuR intelligent pill dispenser. 12

13 Compliance: PHARMAGEST's E-Health answers A global compliance management platform for patients offered by PHARMAGEST INTERACTIVE Providing clear information LGPI / dosage regimens and labels Avoiding forgotten doses Ma Pharmacie Mobile / Medication reminder Detecting non-compliant patients LGPI / Targeted questionnaire during dispensing Ensuring that medication is taken DO-Pill SecuR / The intelligent pill dispenser Renewing treatment SST / reminders by text or Understanding and being in control of treatment LSO / Compliance Monitoring Software 13

14 Compliance: Conclusion E-Health Its innovation strategy in the field of e-health and patient services via the pharmacist today allows the PHARMAGEST Group to occupy a leading position as an infrastructure operator and provider - For pharmacists, the Group's traditional customers, by providing them with the tools they need to support patients in compliance with the new roles attributed to them under the HPST Act (Hôpitaux, Patients, Santé et Territoires [Hospitals, Patients, Health and Territories], 2009); - For the pharmaceutical industry interested in the possibilities opened up by the PHARMAGEST Group's offering (the first contract with a pharmaceutical laboratory in this field has been signed and should be implemented); - For private customers and public authorities who can integrate these tools into their offerings for their members/the public. 14

15 Financial results on 31 December

16 FINANCIAL RESULTS Key figures for 2014 Sales ( millions) Net profit ( millions) % % Group share of net profit ( millions) + 7% Basic earnings per share ( ) + 9%

17 FINANCIAL RESULTS 2014 Sales In M Change Restated change* Q % 1.1% Q % 6.9% Q % 6.5% Q % 6.7% FY % 5.3% *Restated sales for the "Communication Services" business 17

18 FINANCIAL RESULTS Financial results Sales contribution by business Business contribution to sales 2014 (%) Pharmacy France Pharmacy Belux Care Homes Laboratories e-health 4,9 3,1 9,2 0,7 82,1 Business contribution to sales 2013 (%) Pharmacy France Pharmacy Belux 3,3 3,7 Care Homes 12,8 Laboratories 80,0 18

19 FINANCIAL RESULTS Income statement Financial results in M CHANGE SALES % OPERATING PROFIT % NET PROFIT % NET PROFIT, GROUP SHARE % BASIC EARNINGS PER SHARE % 19

20 FINANCIAL RESULTS Balance Sheet Financial results In M Dec Dec Dec Dec NON-CURRENT ASSETS EQUITY CAPITAL R&D Of which group share Goodwill Other non-current assets NON-CURRENT LIABILITIES LT debts Other non-current liabilities CURRENT ASSETS Accounts receivable CURRENT LIABILITIES Other current assets ST debts Cash Trade creditors Securities available for sale* Other non-current liabilities TOTAL TOTAL * And other financial assets 20

21 FINANCIAL RESULTS Summary cash flow table In M Net cash 31/12/ Self financing capacity Change in WCR (incl. taxes paid) Investments (*) Dividends Loans Other financial operations Net cash 31/12/ (*) of which R&D 2,058 K 21

22 FINANCIAL RESULTS Financial results RATIOS Cash flow 14.9m 16.1m 18.0m GEARING (*) % % % R.O.E. 21 % 21 % 21 % (*) net debt including securities available for sale and other financial assets 22

23 MARKET CAPITALISATION Market Capitalisation On 31/12/2014, market capitalisation reached 303 M. On 20/03/2015, it stood at 361 M. Source: Euronext 23

24 MARKET CAPITALISATION Market Capitalisation Division of the nominal share value Proposal to divide the nominal value of the share by 5, changing it from its current value of 1 to 0.20, The number of shares should therefore be multiplied by 5. The share capital would be composed of 15,174,125 shares of 0.20 instead of 3,034,825 shares of 1. Source: Euronext 24

25 2014 Activity and Outlook 25

26 PHARMACY France Pharmacy France 2014 sales: +3.7% at 94.1 million Represents 82.1% of overall Group sales Increase of 3.7 % in sales driven by: - Configuration sales +3.1%, - Maintenance up + 4.5%, - Developed products (licences and satellite products) + 4.4%. Following the conclusion of negotiations on dispensing fees, pharmacists have resumed their investments, which has allowed the business to experience good growth. 26

27 PHARMACY FRANCE - Key events 1 st software provider to obtain the NF Service "Customer Relations" certification* for its Centralised Software Support services. A new element which distinguishes PHARMAGEST from its competitors and will allow new market shares to be won; Recognition of the quality of service; Even more efficient organisation and a reaffirmation of our commitment to our clients. *Certification obtained in December 2014 and published in March

28 PHARMACY France - Key events - A team of consultants throughout France, - A structured approach: - Strengthening of our service offering and our expertise, - Development of the use of our solutions and the loyalty of our customers, - Detection of opportunities and development of additional income from the sale of services and solutions. Offer launched start of 2014 Sales achieved: 817 K Missions achieved:

29 PHARMACY FRANCE - Key events New market PHARMAGEST INTERACTIVE has signed a strong partnership with the Mutual Pharmacists network Objective: adaptation of LCPI Global Services to meet the specific needs of mutualist pharmacies; As of today, 12 pharmacies have been equipped with the software; Potential: 68 remaining pharmacies. 29

30 PHARMACY FRANCE - Outlook A Global Compliance Platform to make the pharmacist the central actor in this field The Compliance Monitoring Software 100% of clients equipped with the software in 2015 Integration with the pharmacy management software (targeting, opening, access etc.); Secure application: hosted on a HDS server; Coupled with connected solutions and products (intelligent pill dispenser, mobile applications, health devices).

31 PHARMACY FRANCE - Outlook A Global Compliance Platform to make the pharmacist the central actor in this field DO-Pill SecuR The intelligent pill dispenser PHARMAGEST INTERACTIVE has taken the decision to launch marketing to the general public, via pharmacists without waiting for the results of national and regional test projects for which the PHARMAGEST Group has been selected, such as: -PAERPA (Older People at Risk of Losing their Independence), -E-NEPHRO / E-CHRONIC, and with the aim of studying, at the medico-economic level, the possibility of reimbursement of the pill dispenser in the case of use in certain illnesses. 31

32 PHARMACY FRANCE - Outlook A Global Compliance Platform to make the pharmacist the central actor in this field DO-Pill SecuR The intelligent pill dispenser Help with compliance (avoiding forgotten doses), Ensuring that medication is taken, Improving the quality of life of patients, A reassuring product for patients and their family members. 500,000 The potential number of patients in France for whom the DO-Pill SecuR could be a real solution, 40% 40% of French people believe that the electronic pill dispenser could help them follow their treatment. 32

33 PHARMACY FRANCE - Outlook New Expertise For the first time, the HEALTHLEASE subsidiary, specialised in the financing of pharmacy equipment, contributed 100% over a whole year to the PHARMAGEST Group net income, at a total of 1.2 million. Until the end of 2014, HEALTHLEASE was dependent on an external service provider for its business. A marketplace for the financing of equipment From January 2015, thanks to the creation of a new subsidiary, NANCEO, and significant developments, the PHARMAGEST Group has expanded its expertise: - To make it independent from a technological point of view, - To allow it to integrate the margin of technical services, - To allow it to offer white label utilisation of the technical platform to other companies. 33

34 PHARMACY BELUX Pharmacy BeLux 2014 sales: % at 3.5 million Represents 3.1 % of overall Group sales Configuration sales % (on a base of 1.5 million), Recurring revenues: + 9.3% (on a base of 1.8 million), Sales of developed products: % (on a base of 0.2 million). Business in 2014 has been marked by commercial transformation difficulties, but the recovery of the target commercial organisation augurs well for a recovery in business for

35 PHARMACY BELUX - Key events Pharmacy BeLux H2 marked by the development and roll-out of new functions and new additional modules in Belgium and Luxembourg: New management of patient consent in the DPP (Shared Pharmaceutical File), New management of the right of midwives to prescribe medication, Delivery of a new medication schedule for monitoring patient treatment, Option to centralise all payments for a pharmacy to a single cash register, Replacement of predefined product orders by a single product, New offer management, Installation of a new storehouse module in almost 50 pharmacies belonging to 3 different chains, New digitalisation module for documents compatible with Spigraph, Addition of a new IP/ethernet communication layer for the robotic system interface, 35

36 PHARMACY BELUX Outlook - Outlook - Pharmacy BeLux Consolidation of the innovative products offering: The delivery of the medication unit pricing module for nursing and care homes, for all of our Belgian software, in compliance with the obligation effective as of 1 April 2015, Roll-out of Ma Pharmacie Mobile (My Mobile Pharmacy) on the markets in Belgium and Luxembourg. The launch of Offiboard, a new application for mobiles and tablets allowing key pharmacy data to be consulted in real time, The implementation of Vitalink, which facilitates the sharing of medication schedules between pharmacies and nursing and care homes, The roll-out in 2015 of AssurPharma with certification of compliance for SABCO solutions. This new service will permit the secure electronic transmission of data relating to BVAC records from the pharmacy to the patient's health insurance company, Objectives: to accelerate the acquisition of new customers and establish the growing reputation of SABCO and the image of a professional company serving pharmacists 36

37 LABORATORIES Laboratories 2014 sales: 10.5 M % representing 9.2 % of the Group's overall sales In an economic and regulatory context undergoing profound changes: Classic Laboratories business: +12.8% Communication services: % It should be noted that the drop in Communication Services business, given its low margin, has a positive impact on the profitability of the Laboratories business. As announced, the Communication Services business will almost disappear in

38 LABORATORIES - Key events 2014 report Ethical laboratories have confirmed their interest in products for providing information during dispensing or in the LGPI Global Services portal, notably in the context of initial hospital prescriptions or to encourage correct use of medication. Significant drop in products for sales promotion during dispensing but increasing demand for products for communicating with the general public. We are working with 50 pharmaceutical companies on contextual pop-up, and PharmaMixMedia campaigns and related sales, as well as on surveys and observatories. 38

39 LABORATORIES - Key events PHARMA OBSERVATORY January: Retirement February: Uncertainty at the counter March: Protection of healthcare data April: Behind the scenes at the pharmacy May: Are the white coats feeling blue? June: The place of students in pharmacies September: The automatic pharmacy - not so straight-forward! October: Unit dispensing, a divisive subject! November: Pharmacists taking action! December: Vaccination at the pharmacy, you say no! WELL-BEING & HEALTH OBSERVATORY February: Tired, stressed, depressed Communication campaigns 2014 HEALTH DAYS -5 operations carried out -10,892 patients questioned -1,436 advice sheets handed out SURVEYS/OBSERVATORIES 25 operations carried out INFORMATION DURING DISPENSING (pop up) 14 campaigns carried out RELATED SALES DURING DISPENSING 16 operations carried out PHARMACY TEAM INFORMATION (Pharma Mix Media) - 14 information campaigns carried out via the portal campaigns sent

40 LABORATORIES Outlook Outlook for 2015 Historical Laboratories business: Maintaining of the Consulting e-business strategy with research for new opportunities within the pharmaceutical industry and increased service density: EARLY DETECTION & COMPLIANCE offer, from initial screening for at-risk profiles to assistance for patients, PATIENT BEHAVIOUR OBSERVATION offer, which will be added to the current STUDIES and ADVICE offer: observation of sales and the market, OTC studies, media impact studies, Global offer to help pharmacy teams from the moment an order is taken, giving them a better awareness of biosimilar products or other niche products. 40

41 CARE HOMES Care Homes H Sales: 5.64 million, up 33.4% representing 4.9% of the Group's overall sales Developed products (licenses and satellite offers) up 32.4%, Recurring revenues increased by 29.2%. 41

42 CARE HOMES - Key events In 2014, MALTA INFORMATIQUE was confirmed as a leader in its market MALTA INFORMATIQUE became the second largest actor in its market in Sharp increase in number of new equipped sites signed (222 vs 162 for 2013): Installed base of over 1,150 facilities, Market share greater than 10%. The roll-out of several major Group contracts continued in very good conditions (ACPPA Group, EMERA Group, Centre Action Social de la Ville de Paris, SGMR Group). 42

43 CARE HOMES - Key events Care Homes Commercial success boosted by software upgrades: Double HAS certification for outpatient and hospital prescription assistance software obtained for the TITAN SOIN module. MALTA INFORMATIQUE is the only actor on the medico-social market to have obtained this double certification, which strengthens our image as an expert in the medication circuit field; Major functional upgrade in 2014 with the launch of a new version integrating major developments in billing and care. 43

44 CARE HOMES - Outlook Outlook - Care Homes MALTA INFORMATIQUE is serene on maintaining a good level of organic growth and recurring revenues. The context remains favourable: over 1,150 facilities not equipped, an active software upgrade market and a very stable tripartite financing structure (State - regional authority - resident). Thanks to the Group's numerous contracts and the maturity of the marketing team, MALTA INFORMATIQUE benefits from excellent commercial visibility that augur well for strong growth in MALTA INFORMATIQUE's line-up will be added to with TITAN NOMADE, which allows medical personnel to access medical information offline and on the go. This module was developed in 2014 and its commercial launch will begin in MALTA INFORMATIQUE is working to develop a new TITAN WEB ENTOURAGE module designed for residents' friends, family and carers in order to allow elderly residential care homes to communicate information on the life of the facility and care for the residents. 44

45 E-HEALTH 2014 sales: 0.8 M, strong growth representing 0.7% of the Group's overall sales First returns on investments for the new e-health business. The sales revenue is mainly driven by the sale of products for the new business specialised in health devices. 45

46 E-HEALTH - Key events KAPELSE, designer of innovative e- Health solutions Two target markets: Telehealth Medical tele-monitoring Medical tele-assistance Medico-social tele-assistance Equipment for healthcare professionals Digitisation and enhanced security of administrative documents, Robust authentication for access to teleservices and shared records, Patient monitoring. 46

47 E-HEALTH - Key events KAPELSE, designer of innovative e- Health solutions From its launch in May 2014: -Over 6,000 SESAM-Vitale health card readers installed -As of 31 December 2014: - 70% of sales revenue came from PHARMAGEST INTERACTIVE customers; - 30% was from customers of other software providers. Supports the strategy of opening up to pharmacies beyond clients of the PHARMAGEST Group and other health professionals. 47

48 E-HEALTH Outlook In 2015, two major contracts signed with private partners will be implemented One with a pharmaceutical laboratory, The other with a large health insurance group. Objective: Implementation of optimised and coordinated payments for patients with chronic illnesses, from early screening to compliance monitoring. The business model selected: Pay per use billing for the services offered. Supports the investment strategy in e-health in the fields of Expert systems (DIATELIC), Personal Health Data Hosting, Compliance monitoring (the DO-Pill SecuR pill dispenser). Forming a Global Compliance Platform 48

49 Conclusion 49

50 CONCLUSION Conclusion The coherence of the strategy of diversification towards e-health is starting to be seen in the figures, results and on the health market. The e-health business model is defined and the first contracts signed are going to be implemented; All of the PHARMAGEST Group's activities will benefit from the provision of the Global Monitoring Platform for the development of new added-value services. Thanks to its innovation and the provision of new solutions for private and public healthcare actors, the PHARMAGEST Group will occupy an important place on this market. The investments needed for this diversification have been made possible by the excellent performances of the Group s historical activities, the foundations on which the PHARMAGEST Group has been built. 50

51 CONCLUSION Conclusion The PHARMAGEST Group is maintaining its external growth policy by exploring avenues both in France and overseas in the following development areas: The services and technologies that it could deliver to its pharmacist clients to help them fully accomplish their new missions for advising patients; The technological areas that will enable the group to develop new products or services to enhance the profitability of pharmacies and/or the efficiency of health systems. 51

52 Next key dates Financial reports: Release of the 2015 registration document: end-april May 2015: Publication of Q1 sales 06 August 2015: Publication of H1 sales Next key dates for investors: 26 June 2015: Annual General Meeting, Head office 52

53 Contacts Contacts Managing Director Dominique PAUTRAT Shareholder & Investor Relations Jean-Yves SAMSON Tel.: Press Officer FIN EXTENSO Isabelle APRILE Tel i.aprile@finextenso.fr 53

54 54